Single Port Robotics
Single Port Robotic Surgery
Hackensack University Medical Center: The First Hospital in New Jersey to Use the Latest Innovation in Robotic Surgery
Hackensack University Medical Center is the first hospital in New Jersey to successfully perform surgeries using the da Vinci SP® Surgical System, which inserts all surgical instruments through one small abdominal incision, improving surgical outcomes and allowing quicker patient recovery.
In June 2018, the U.S. Food and Drug Administration (FDA) cleared the da Vinci SP system for urologic surgical procedures that are appropriate for a single port approach. A renowned center of excellence for robotic surgery, Hackensack University Medical Center was one of only 10 sites in the U.S. selected to launch the new platform.
Site selection was based on breadth of experience in robotic surgery. The medical center’s five urologic surgeons have performed a combined total of over 8,500 robotic surgeries — a number which places the team well within the top echelon in the field.
The da Vinci SP system includes three, multi-jointed, wristed instruments and the first da Vinci fully wristed 3D HD camera. The technology’s revolutionary design enables single port surgery, narrow access surgery, triangulation and 360-degree rotation. To date the team has used the new technology to perform:
- Partial nephrectomy
- Radical nephrectomy
- Radical prostatectomy
- Pyeloplasty
- Ureteroplasty
- Ureteroplasty with mucosal graft
Surgical outcomes have been excellent, with zero conversions to multi-port or open surgical alternatives.
Single Port Robot to Be Used for Tonsil and Tongue Cancers
The FDA recently cleared the da Vinci SP for radical tonsillectomy and tongue base resection, and the medical center’s otolaryngology (ENT) specialists will begin using the single port technology by summer 2019. The flexibility of these instruments gives ENT surgeons a significant advantage over the older technology, allowing them to work easily within a very small space. The new technology will be used to treat tonsil and tongue cancer, which is on the rise due to a spike in HPV related cancers.
The medical center anticipates additional submissions for FDA approval in in a number of specialties, including colorectal surgery.
